Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Perianal Fistulizing Crohn's Disease
NCT04519671Phase 2Terminated
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in Crohn's disease comparing Mesenchymal Stem Cells with Placebo (2 arms). Primary endpoint: Treatment related adverse events at 6 months. Started Nov 2020; status: terminated.
02
Drugs
mesenchymal stem cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04519671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519671.